TrialVaccine2023

An evaluation of the safety and immunogenicity of MVC-COV1901: Results of an interim analysis of a phase III, parallel group, randomized, double-blind, active-controlled immunobridging study in Paraguay.

Julio Torales et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.